Lack of inhibitory effect of octreotide on intestinal adaptation in short bowel syndrome in the rat.
Octreotide is a long-acting analogue of somatostatin, which is effective in the treatment of secretory diarrhea in a number of disorders including short bowel syndrome. Its use in this syndrome has been limited because of concerns about potential adverse effect on intestinal adaptation, because it inhibits a number of trophic hormones. This study was conducted to determine whether octreotide inhibits intestinal adaptation in a rat model of short bowel syndrome. Thirty male Sprague-Dawley rats were divided into four treatment groups, eight receiving 80% small-bowel resection and treated with 2.25 microg/kg(-1) per day(-1) of octreotide, eight receiving 80% small-bowel resection and treated with 25 microg/kg(-1) per day(-1) of octreotide, eight receiving 80% small-bowel resection with saline control, and six receiving sham operation with saline control. Mucosal weight, protein, and sucrase levels were subsequently analyzed after 2 weeks of therapy. Massive adaptation occurred in all three groups relative to sham-operated controls. However, neither the pharmacologic nor the much higher dose of octreotide demonstrated any adverse effects on intestinal adaptation. In our animal model, octreotide does not inhibit intestinal adaptation after massive small-bowel resection.